As such, we hypothesize that anti-CTLA4 agents will negatively impact the ability for fetal-like FOLR2+ TAMs to induce the expansion of Tregs in HCC, subsequently reducing the immunosuppressive TME and increasing the likelihood of therapy response. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.